GK-2

What is GK-2?

GK-2 is a synthetic dimeric dipeptide designed to mimic the fourth beta-turn loop of nerve growth factor (NGF), the region of the protein that contacts the TrkA receptor. It was developed by the medicinal chemistry group of Tatiana Gudasheva and Sergei Seredenin at the V.V. Zakusov Research Institute of Pharmacology (Russian Academy of Medical Sciences, Moscow) as part of a long-running program to build small, drug-like molecules that reproduce the neurotrophic signaling of NGF while avoiding the hyperalgesia — pain sensitization — that has limited full-length recombinant NGF as a clinical drug. In animal models, GK-2 has shown neuroprotective effects in stroke, traumatic brain injury, Parkinson's-like lesions, and depression paradigms. It remains primarily a preclinical research compound; no completed Western human clinical trials have been published.

What GK-2 Is Investigated For

GK-2 is investigated almost entirely in preclinical models for neuroprotection — stroke, traumatic brain injury, Parkinson's-like dopaminergic lesions, Alzheimer's-relevant amyloid paradigms — and for antidepressant-like effects, based on its design as a dipeptide mimetic of the TrkA-binding fourth loop of nerve growth factor. The strongest evidence is mechanistic and animal-level: multiple published papers from the Gudasheva and Seredenin group at the Zakusov Institute document TrkA phosphorylation, downstream PI3K/Akt activation, and protective effects in rodent ischemia, MPTP, streptozotocin-diabetes and forced-swim models. The central pharmacological selling point is a post-receptor split: GK-2 activates mainly the PI3K/Akt branch below TrkA and, unlike its loop-1 sibling GK-6, does not activate the MAPK/ERK branch that the originating group associates with NGF's hyperalgesia problem. The honest caveats are substantial: there are no completed Western-published human clinical trials, most of the literature comes from a single Russian research program, independent replication outside that lineage is limited, and GK-2 itself is not an approved medicine in any jurisdiction despite the broader Gudasheva dipeptide-design program having produced other compounds in Russian clinical channels.

History & Discovery

GK-2 is the product of a decades-long medicinal-chemistry program at the V.V. Zakusov Research Institute of Pharmacology of the Russian Academy of Medical Sciences in Moscow, led by Tatiana Gudasheva in collaboration with institute director Sergei Seredenin. The program's central thesis is unusual and, in its own terms, elegant: take a large neurotrophic protein (NGF, BDNF, GDNF) whose clinical development has been limited by poor pharmacokinetics, blood-brain barrier exclusion, and off-target side effects, identify the short beta-turn loop of the protein that makes the critical receptor contact, and synthesize a small, drug-like peptide mimetic of just that loop. The hope is to capture the desired receptor signaling in a molecule that is orders of magnitude smaller, more stable, and more amenable to systemic dosing. GK-2 is the flagship NGF mimetic from this program. Structurally it is a dimeric dipeptide — two monosuccinyl-glutamyl-lysine fragments joined by a hexamethylenediamine linker — modeled on the fourth beta-turn loop of NGF, the region most closely associated with TrkA receptor contact. In published pharmacology it engages TrkA, activates PI3K/Akt signaling without engaging MAPK/ERK, and shows neuroprotective activity in rodent stroke, Parkinson's, Alzheimer's, diabetes and depression models. The group has explicitly pointed to that PI3K-only signalling pattern as the reason it does not reproduce the hyperalgesia that has dogged full-length NGF in clinical development for conditions like diabetic neuropathy and Alzheimer's disease. GK-2 is the NGF analogue in a broader family of loop-mimetic dipeptides from the same group. Its BDNF-mimetic sibling, GSB-106, models a loop of brain-derived neurotrophic factor at the TrkB receptor using the same design grammar. Despite substantial preclinical literature and mechanistic detail, GK-2 itself has not reached published Western clinical trials. A few compounds from the broader Gudasheva platform have progressed into Russian clinical channels; GK-2 has not. The program is the most well-developed attempt in the Russian peptide-pharmacology tradition to bridge from large neurotrophin biology to small-molecule drug design, and the preclinical record is substantially thicker than for most Russian research peptides of comparable vintage.

How It Works

GK-2 is a small molecule designed to copy just the part of nerve growth factor (NGF) that tells brain cells to survive and grow. The idea is to keep NGF's helpful brain effects while leaving out the part of NGF signaling that causes pain sensitivity.

GK-2 is a dimeric dipeptide — two monosuccinyl-glutamyl-lysine units joined through a hexamethylenediamine linker — modeled on the fourth beta-turn loop of the NGF protein. In cell and animal studies from the Gudasheva and Seredenin laboratory, GK-2 engages the TrkA receptor, promoting its phosphorylation and activating the downstream PI3K/Akt pathway. Unlike full-length NGF and unlike its loop-1 sibling GK-6, GK-2 does not activate the Ras/MAPK (ERK) cascade: its neuroprotection is abolished by the PI3K inhibitor LY294002 but not by the MEK1/2 inhibitor PD98059, and in the same comparison GK-6 raised both ERK and Akt phosphorylation while GK-2 raised only Akt. A central claim in the program's literature is therefore not about receptor choice at all — GK-2 and NGF both act at TrkA, but GK-2 engages only one branch downstream. Because the MAPK/ERK branch is the one the group associates with NGF-induced hyperalgesia (GK-6 lowered the rat tail-flick pain threshold, GK-2 did not), this post-receptor split is the proposed molecular basis for GK-2's ability to deliver NGF-like neuroprotection without producing the pain sensitization that has troubled clinical development of recombinant NGF. In rodent models of cerebral ischemia, MPTP-induced parkinsonism, amyloid toxicity, and behavioral despair, GK-2 has shown neuroprotective and antidepressant-like activity at low milligram-per-kilogram doses administered intraperitoneally or intravenously.

Evidence Snapshot

Research Gaps & Open Questions

What the current literature has not yet settled about GK-2:

• 01Human clinical trials — no completed Phase I, II, or III studies of GK-2 have been published in Western indexed literature; human pharmacokinetics, tolerability, and efficacy are uncharacterized.
• 02Independent replication — most of the pharmacology comes from the Gudasheva and Seredenin laboratory at the Zakusov Institute; independent reproduction in Western and non-affiliated Russian groups is limited.
• 03Signalling-selectivity confirmation — the claimed PI3K-without-MAPK pattern that underwrites the no-hyperalgesia argument rests on the originating group's own inhibitor experiments and needs independent replication in human cells and in primate pain models.
• 04Long-duration oncology safety — TrkA signaling contributes to proliferation in several tumor types (including TrkA-expressing neuroblastoma and some adult cancers); formal carcinogenicity and tumor-promotion studies in susceptible models are absent from the public literature.
• 05Route and formulation — published animal work uses parenteral dosing; oral dosing is active in rodents at 5-10 mg/kg, but intranasal and other patient-friendly routes are unvalidated and no human bioavailability data exist.
• 06Comparative effectiveness — direct comparisons of GK-2 versus Cerebrolysin, Dihexa, or other neurotrophic-mimetic strategies in shared preclinical paradigms are sparse.
• 07Program-level prioritization — the Gudasheva and Seredenin group's 2025 publication arc has shifted toward NT-3 dipeptide mimetics (GTS-301, GTS-302) for analgesia and opioid-withdrawal applications rather than additional GK-2 work, which raises the question of whether GK-2 remains an active development candidate within the originating program or has been deprioritized in favor of sister compounds.

Forms & Administration

In published animal studies, GK-2 has been administered intraperitoneally at 0.01-5 mg/kg, intravenously at 1-10 mg/kg, and orally at 5-10 mg/kg (oral activity is established in rodents, not merely theoretical). There is no established human route, dose, or schedule. GK-2 is a research compound and not available as a clinician-prescribed or compounded medicine.

Common Questions

Who GK-2 Is NOT For

Drug & Supplement Interactions

No formal drug-interaction studies for GK-2 exist in the public literature. Theoretical considerations follow from the TrkA-biased signaling mechanism and the broader pharmacology of co-administered CNS-active medications. Concurrent use with anticancer kinase inhibitors that target Trk receptors (entrectinib, larotrectinib, repotrectinib for NTRK-fusion cancers) would be pharmacologically antagonistic and is not appropriate. Concurrent use with serotonergic antidepressants, ketamine, psychedelics, or other agents that modulate BDNF-TrkB signaling could theoretically interact at the level of overlapping neurotrophin downstream pathways (PI3K/Akt, MAPK), though no clinical data exist. Concurrent administration with the sibling BDNF-mimetic GSB-106 is common in the originating program's preclinical work but has not been characterized for safety or for additive vs antagonistic effects in any controlled setting. Patients on any chronic medication who are considering GK-2 (in a research protocol) should disclose all concurrent agents to the investigator.

Safety Profile

Legal Status

Regulatory status changes over time. Verify current local rules with a qualified professional.

Myths & Misconceptions